Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study ( NCT06248008) evaluating ...

Acne is the most common skin condition in the United States and its effects can be devastating. However, successful treatment can be hard to come by. "I have had problems with my skin for as long as I ...

Sagimet Biosciences (SGMT) lost ~9% in the premarket on Thursday after Ascletis Pharma (ASCLF), its Chinese licensing partner ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Picture this: You just got out of bed after a long night’s rest and you’re feeling super refreshed and ...

Please provide your email address to receive an email when new articles are posted on . Topical triple-agent fixed-dose combination had the best log-ratio for treatment success. It also proved to be ...

It’s the bane of many people’s existences – acne. It can feel like the only thing you see when you look at a photo or when you’re putting on makeup. Acne can cause not only skin discomfort and ...

Among nearly 20 different agents and treatment combinations, topical triple-agent fixed-dose combination (FDC) gel emerged as the most efficacious for moderate-to-severe acne. Researchers who ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...